Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 4/20 | 0.38 |
| ▸ | FEN1 | P39748 | 4/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.35 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12733946 | 0.91 | USP7 (0.37) | ALOX5APFEN1FFAR1NAAAFFAR4 | |
| SCHEMBL12716345 | 0.90 | ALOX5AP (0.40) | ALOX5APFEN1CYP11B1CYP11B2KDM1A | |
| SCHEMBL12733955 | 0.89 | FFAR4 (0.40) | ALOX5APFEN1FFAR1FFAR4 | |
| SCHEMBL12740361 | 0.88 | NAAA (0.43) | ALOX5APFEN1FFAR1NAAAFFAR4 | |
| SCHEMBL12739910 | 0.88 | FFAR4 (0.37) | ALOX5APFEN1FFAR1FFAR4 | |
| SCHEMBL12736836 | 0.88 | NAAA (0.39) | ALOX5APFEN1FFAR1NAAAFFAR4 | |
| SCHEMBL12736186 | 0.87 | FFAR1 (0.41) | ALOX5APFEN1FFAR1 | |
| SCHEMBL12740788 | 0.87 | FFAR1 (0.41) | FFAR1 | |
| SCHEMBL12735203 | 0.87 | FFAR4 (0.37) | ALOX5APFEN1FFAR1FFAR4 | |
| SCHEMBL12734336 | 0.86 | ERN1 (0.34) | ALOX5APFEN1FFAR1NAAAFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | ALOX5AP 1673/4885FEN1 3340/4885FFAR1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.